aTyr Pharma Inc (NASDAQ:LIFE) – Analysts at William Blair issued their Q1 2017 earnings per share (EPS) estimates for shares of aTyr Pharma in a research report issued to clients and investors on Friday. William Blair analyst Y. Xu anticipates that the firm will earn ($0.49) per share for the quarter. William Blair also issued estimates for aTyr Pharma’s Q2 2017 earnings at ($0.50) EPS, Q3 2017 earnings at ($0.55) EPS, Q4 2017 earnings at ($0.63) EPS and FY2019 earnings at ($3.96) EPS.
Several other equities analysts have also weighed in on LIFE. JPMorgan Chase & Co. lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating and set a $2.85 price objective for the company. in a research report on Tuesday, December 13th. BMO Capital Markets restated a “market perform” rating and set a $4.00 price objective (down previously from $8.00) on shares of aTyr Pharma in a research report on Thursday, December 15th. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Citigroup Inc raised their price objective on shares of aTyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating, aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $3.71.
Your IP Address:
aTyr Pharma (NASDAQ:LIFE) opened at 3.70 on Monday. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $6.01. The company’s 50-day moving average is $3.46 and its 200 day moving average is $3.07. The firm’s market cap is $87.76 million.
In other aTyr Pharma news, Director Paul Schimmel acquired 25,000 shares of aTyr Pharma stock in a transaction dated Wednesday, December 21st. The stock was bought at an average price of $2.28 per share, for a total transaction of $57,000.00. Following the transaction, the director now owns 40,440 shares in the company, valued at approximately $92,203.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 28.90% of the company’s stock.
An institutional investor recently bought a new position in aTyr Pharma stock. EcoR1 Capital LLC bought a new stake in aTyr Pharma Inc (NASDAQ:LIFE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 976,986 shares of the company’s stock, valued at approximately $2,101,000. aTyr Pharma accounts for about 0.7% of EcoR1 Capital LLC’s portfolio, making the stock its 20th largest position. EcoR1 Capital LLC owned approximately 4.12% of aTyr Pharma as of its most recent filing with the SEC. Institutional investors own 44.84% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.